Management of cardiogenic shock complicating myocardial infarction

Alexandre Mebazaa; Alain Combes; Sean van Diepen; Alexa Hollinger; Jaon N. Katz; Giovanni Landoni; Ludhmila Abrahao Hajjar; Johan Lassus; Guillaume Lebreton; Gilles Montalescot; Jin Joo Park; Susanna Price; Alessandro Sionis; Demetris Yannopolos; Veli Pekka Harjola; Bruno Levy; Holger Thiele

doi:10.1007/s00134-018-5214-9

Management of cardiogenic shock complicating myocardial infarction

Alexandre Mebazaa, Alain Combes, Sean van Diepen, Alexa Hollinger, Jaon N. Katz, Giovanni Landoni, Ludhmila Abrahao Hajjar, Johan Lassus, Guillaume Lebreton, Gilles Montalescot, Jin Joo Park, Susanna Price, Alessandro Sionis, Demetris Yannopolos, Veli Pekka Harjola, Bruno Levy, Holger Thiele

Research output: Contribution to journal › Review article › peer-review

126 Scopus citations

Abstract

Up to 10% of acute coronary syndromes are complicated by cardiogenic shock (CS) with contemporary mortality rates of 40–50%. The extent of ischemic myocardium has a profound impact on the initial, in-hospital, and post-discharge management and prognosis in this patient population. Individualized patient risk assessment plays an important role in determining appropriate revascularization, drug treatment with inotropes and vasopressors, mechanical circulatory support, intensive care support of other organ systems, hospital level of care triage, and allocation of clinical resources. This review will outline the underlying causes and diagnostic criteria, pathophysiology, and treatment of CS complicating acute coronary syndromes with a focus on (a) potential therapeutic issues from the perspective an interventional cardiologist, an emergency physician, and an intensive care physician, (b) the type of revascularization, and (c) new therapeutic advancements in pharmacologic and mechanical percutaneous circulatory support.

Original language	English (US)
Pages (from-to)	760-773
Number of pages	14
Journal	Intensive Care Medicine
Volume	44
Issue number	6
DOIs	https://doi.org/10.1007/s00134-018-5214-9
State	Published - Jun 1 2018

Bibliographical note

Funding Information:
AM received lecture fees from Novartis, Orion, and Abbott, research grants from Roche, and consultant fees from Servier and Sanofi. GL received speaker fees from Orion, Abbvie, and Tenax (companies producing or commercializing levosimendan). BL received lecture fees from Pulsion, Baxter, Orion, and Lilly, and consultant fees from Novartis, Orion, and Baxter. Other coauthors have no conflicts to declare.

Publisher Copyright:
© 2018, Springer-Verlag GmbH Germany, part of Springer Nature and ESICM.

Keywords

Acute myocardial infarction
Cardiogenic shock
Catecholamines
Mechanical circulatory support

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1007/s00134-018-5214-9

Find It

Find It at U of M Libraries

Cite this

Mebazaa, A., Combes, A., van Diepen, S., Hollinger, A., Katz, J. N., Landoni, G., Hajjar, L. A., Lassus, J., Lebreton, G., Montalescot, G., Park, J. J., Price, S., Sionis, A., Yannopolos, D., Harjola, V. P., Levy, B., & Thiele, H. (2018). Management of cardiogenic shock complicating myocardial infarction. Intensive Care Medicine, 44(6), 760-773. https://doi.org/10.1007/s00134-018-5214-9

Mebazaa, A, Combes, A, van Diepen, S, Hollinger, A, Katz, JN, Landoni, G, Hajjar, LA, Lassus, J, Lebreton, G, Montalescot, G, Park, JJ, Price, S, Sionis, A, Yannopolos, D, Harjola, VP, Levy, B & Thiele, H 2018, 'Management of cardiogenic shock complicating myocardial infarction', Intensive Care Medicine, vol. 44, no. 6, pp. 760-773. https://doi.org/10.1007/s00134-018-5214-9

@article{5cad9a519b144b648d85c215c00f37a4,

title = "Management of cardiogenic shock complicating myocardial infarction",

abstract = "Up to 10% of acute coronary syndromes are complicated by cardiogenic shock (CS) with contemporary mortality rates of 40–50%. The extent of ischemic myocardium has a profound impact on the initial, in-hospital, and post-discharge management and prognosis in this patient population. Individualized patient risk assessment plays an important role in determining appropriate revascularization, drug treatment with inotropes and vasopressors, mechanical circulatory support, intensive care support of other organ systems, hospital level of care triage, and allocation of clinical resources. This review will outline the underlying causes and diagnostic criteria, pathophysiology, and treatment of CS complicating acute coronary syndromes with a focus on (a) potential therapeutic issues from the perspective an interventional cardiologist, an emergency physician, and an intensive care physician, (b) the type of revascularization, and (c) new therapeutic advancements in pharmacologic and mechanical percutaneous circulatory support.",

keywords = "Acute myocardial infarction, Cardiogenic shock, Catecholamines, Mechanical circulatory support",

author = "Alexandre Mebazaa and Alain Combes and {van Diepen}, Sean and Alexa Hollinger and Katz, {Jaon N.} and Giovanni Landoni and Hajjar, {Ludhmila Abrahao} and Johan Lassus and Guillaume Lebreton and Gilles Montalescot and Park, {Jin Joo} and Susanna Price and Alessandro Sionis and Demetris Yannopolos and Harjola, {Veli Pekka} and Bruno Levy and Holger Thiele",

note = "Funding Information: AM received lecture fees from Novartis, Orion, and Abbott, research grants from Roche, and consultant fees from Servier and Sanofi. GL received speaker fees from Orion, Abbvie, and Tenax (companies producing or commercializing levosimendan). BL received lecture fees from Pulsion, Baxter, Orion, and Lilly, and consultant fees from Novartis, Orion, and Baxter. Other coauthors have no conflicts to declare. Publisher Copyright: {\textcopyright} 2018, Springer-Verlag GmbH Germany, part of Springer Nature and ESICM.",

year = "2018",

month = jun,

day = "1",

doi = "10.1007/s00134-018-5214-9",

language = "English (US)",

volume = "44",

pages = "760--773",

journal = "Intensive Care Medicine",

issn = "0342-4642",

publisher = "Springer Verlag",

number = "6",

}

TY - JOUR

T1 - Management of cardiogenic shock complicating myocardial infarction

AU - Mebazaa, Alexandre

AU - Combes, Alain

AU - van Diepen, Sean

AU - Hollinger, Alexa

AU - Katz, Jaon N.

AU - Landoni, Giovanni

AU - Hajjar, Ludhmila Abrahao

AU - Lassus, Johan

AU - Lebreton, Guillaume

AU - Montalescot, Gilles

AU - Park, Jin Joo

AU - Price, Susanna

AU - Sionis, Alessandro

AU - Yannopolos, Demetris

AU - Harjola, Veli Pekka

AU - Levy, Bruno

AU - Thiele, Holger

N1 - Funding Information: AM received lecture fees from Novartis, Orion, and Abbott, research grants from Roche, and consultant fees from Servier and Sanofi. GL received speaker fees from Orion, Abbvie, and Tenax (companies producing or commercializing levosimendan). BL received lecture fees from Pulsion, Baxter, Orion, and Lilly, and consultant fees from Novartis, Orion, and Baxter. Other coauthors have no conflicts to declare. Publisher Copyright: © 2018, Springer-Verlag GmbH Germany, part of Springer Nature and ESICM.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Up to 10% of acute coronary syndromes are complicated by cardiogenic shock (CS) with contemporary mortality rates of 40–50%. The extent of ischemic myocardium has a profound impact on the initial, in-hospital, and post-discharge management and prognosis in this patient population. Individualized patient risk assessment plays an important role in determining appropriate revascularization, drug treatment with inotropes and vasopressors, mechanical circulatory support, intensive care support of other organ systems, hospital level of care triage, and allocation of clinical resources. This review will outline the underlying causes and diagnostic criteria, pathophysiology, and treatment of CS complicating acute coronary syndromes with a focus on (a) potential therapeutic issues from the perspective an interventional cardiologist, an emergency physician, and an intensive care physician, (b) the type of revascularization, and (c) new therapeutic advancements in pharmacologic and mechanical percutaneous circulatory support.

AB - Up to 10% of acute coronary syndromes are complicated by cardiogenic shock (CS) with contemporary mortality rates of 40–50%. The extent of ischemic myocardium has a profound impact on the initial, in-hospital, and post-discharge management and prognosis in this patient population. Individualized patient risk assessment plays an important role in determining appropriate revascularization, drug treatment with inotropes and vasopressors, mechanical circulatory support, intensive care support of other organ systems, hospital level of care triage, and allocation of clinical resources. This review will outline the underlying causes and diagnostic criteria, pathophysiology, and treatment of CS complicating acute coronary syndromes with a focus on (a) potential therapeutic issues from the perspective an interventional cardiologist, an emergency physician, and an intensive care physician, (b) the type of revascularization, and (c) new therapeutic advancements in pharmacologic and mechanical percutaneous circulatory support.

KW - Acute myocardial infarction

KW - Cardiogenic shock

KW - Catecholamines

KW - Mechanical circulatory support

UR - http://www.scopus.com/inward/record.url?scp=85047150371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047150371&partnerID=8YFLogxK

U2 - 10.1007/s00134-018-5214-9

DO - 10.1007/s00134-018-5214-9

M3 - Review article

C2 - 29767322

AN - SCOPUS:85047150371

SN - 0342-4642

VL - 44

SP - 760

EP - 773

JO - Intensive Care Medicine

JF - Intensive Care Medicine

IS - 6

ER -

Management of cardiogenic shock complicating myocardial infarction

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this